Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl
Status:
Recruiting
Trial end date:
2023-11-20
Target enrollment:
Participant gender:
Summary
This study is for patients have been using prostaglandin analogue eye drops with a
preservative for 3 months or more and have been diagnosed with prostaglandin-associated
peri-orbital disease.
the investigators would like to confirm the real world evidence(RWE) of safety and efficacy
after changing to Eybelis ophthalmic solution 0.002%.